Abivax SA (ABVX) vs Cogent Biosciences (COGT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Cogent Biosciences (COGT) has outperformed Abivax SA (ABVX) over the past year, gaining 93.1% versus a gain of 2.9%. Abivax SA is the larger company by market cap ($7.77 billion vs $5.22 billion), about 1.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABVX | COGT |
|---|---|---|
| Share price | $89.05 | $30.08 |
| Market cap | $7.77B | $5.22B |
| 1-day change | +2.34% | -0.20% |
| YTD return | -33.97% | -15.32% |
| 1-year return | +2.94% | +93.07% |
| 5-year return | — | +225.54% |
| EPS (TTM) | $-6.08 | $-2.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-328.94M |
| 52-week high | $148.83 | $43.73 |
| 52-week low | $69.81 | $13.78 |
| Distance from 52-week high | -40.17% | -31.21% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +84.17% | +85.57% |
| Average volume | 1.11M | 1.90M |
| Shares outstanding | 87.27M | 173.52M |
| Employees | 98 | 258 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- COGT has outperformed ABVX by 90.1 percentage points over the past year.
About Abivax SA
ABVX stock →ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 98 employees
About Cogent Biosciences
COGT stock →Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 258 employees
ABVX vs COGT FAQ
Which is bigger, Abivax SA or Cogent Biosciences?
Abivax SA (ABVX) is larger, with a market capitalization of $7.77B compared with $5.22B for Cogent Biosciences (COGT).
Which stock has performed better over the past year, ABVX or COGT?
COGT returned +93.07% over the past 12 months, compared with +2.94% for ABVX (price return, excluding dividends). Past performance does not predict future results.
Are Abivax SA and Cogent Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.